- Home
- PSTL vs CMRX Comparison
PSTL vs CMRX Comparison
Compare PSTL & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSTL
- CMRX
- Stock Information
- Founded
- PSTL 2018
- CMRX 2000
- Country
- PSTL United States
- CMRX United States
- Employees
- PSTL N/A
- CMRX N/A
- Industry
- PSTL Real Estate Investment Trusts
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- PSTL Real Estate
- CMRX Health Care
- Exchange
- PSTL Nasdaq
- CMRX Nasdaq
- Market Cap
- PSTL 335.6M
- CMRX 797.3M
- IPO Year
- PSTL 2019
- CMRX 2013
- Fundamental
- Price
- PSTL $13.51
- CMRX $8.54
- Analyst Decision
- PSTL Strong Buy
- CMRX Hold
- Analyst Count
- PSTL 1
- CMRX 4
- Target Price
- PSTL $15.50
- CMRX $8.51
- AVG Volume (30 Days)
- PSTL 162.6K
- CMRX 2.0M
- Earning Date
- PSTL 05-06-2025
- CMRX 04-30-2025
- Dividend Yield
- PSTL 7.20%
- CMRX N/A
- EPS Growth
- PSTL 83.16
- CMRX N/A
- EPS
- PSTL 0.21
- CMRX N/A
- Revenue
- PSTL $76,372,000.00
- CMRX $212,000.00
- Revenue This Year
- PSTL $13.87
- CMRX $2,416.04
- Revenue Next Year
- PSTL $10.76
- CMRX $923.92
- P/E Ratio
- PSTL $63.26
- CMRX N/A
- Revenue Growth
- PSTL 19.87
- CMRX N/A
- 52 Week Low
- PSTL $12.26
- CMRX $0.75
- 52 Week High
- PSTL $15.15
- CMRX $8.55
- Technical
- Relative Strength Index (RSI)
- PSTL 49.47
- CMRX 80.86
- Support Level
- PSTL $12.52
- CMRX $8.50
- Resistance Level
- PSTL $14.35
- CMRX $8.55
- Average True Range (ATR)
- PSTL 0.40
- CMRX 0.02
- MACD
- PSTL -0.04
- CMRX -0.12
- Stochastic Oscillator
- PSTL 58.12
- CMRX 88.89
About PSTL Postal Realty Trust Inc.
Postal Realty Trust Inc is an internally managed real estate corporation that owns and manages properties leased to the United States Postal Service, or the USPS. Its objective is to create stockholder value by generating risk-adjusted returns through expanding its portfolio of owned and managed postal properties leased to the USPS. The majority of the revenue is generated from the rental income received.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.